Get our latest issue now

available for iOS, Android & web

latest issue

Latest issue

June features

How to…
Get investment

Genie in a bottle
Gene therapy is having a renaissance and is set to change the way we think about treating some diseases

Cover story: The immuno-oncology paradigm
Utilising the power of the immune system is a promising new weapon against cancer

Realising the potential of diagnostics
In vitro diagnostics are finally being recognised for the essential role they play in healthcare management

Clinical trials
The era of bring your own arrives in clinical trials

Clinical research
Incremental innovation
We review the highlights from the PharmaTimes International Clinical Researcher of the Year Competition

UK life sciences
Investing in life sciences
We  talk to Cogent Skills and UCB about the UK life sciences environment

Kavita Oberoi OBE, founder and managing director at Oberoi Consulting, discusses life as an entrepreneur

Patient Files
Knowledge is power says multiple sclerosis patient Ali Garzuzi

Click here to see the latest PharmaTimes Magazine

To subscribe go to; digital available from:

download on the app store get it on google play

Outcomes: a gamechanger for pharma

Patient-recorded outcome measures are likely to become a key part of how healthcare is provided, funded and managed. But is industry ready?

Healthcare Writer Lynne Taylor

The British government’s determination to place health outcomes at the heart of NHS decision-making presents UK-based drugmakers with a unique and potentially huge advantage over their global competitors.

Working in collaboration with the NHS to identify a product’s true value – in other words its value to the patient – has the potential to boost levels of medicines uptake and could also lead to products arriving earlier to market, both in the UK and overseas, a PharmaTimes business meeting was told recently. Leading these potentially game-changing opportunities is the NHS patient-recorded outcome measures programme, which began in 2009.

Innovative drugmakers have included PROMs in their clinical trials for many years, and the data have also long been used in observational studies and population health surveys. “We have decades of experience using these instruments and pharma is way ahead of the game. The fact they are now being measured in healthcare systems changes everything,” Professor Nancy Devlin, research director at the Office of Health Economics told the meeting. Indeed, PROMs are likely to become a key part of how all healthcare is provided, funded and managed, The King’s Fund healthcare policy think-tank has forecast.

So what exactly are PROMs and why should this matter to pharma? You can find out by reading the full article online here

See what's coming up in the March issue [PDF]

Visions 2014 supplement


Creating a balance between
 reimbursement and innovation

Real-world data
How to plan early

NHS reform
What more does pharma need to do?

We asked you what the big developments in 2014 will be?

Change is key to opportunity
What to adapt for

Salesforce effectiveness
Future-proofing the sales team

Myeloma research
An example of a new R&D model

Visions in a nutshell

The complete Visions 2014 supplement PDF is available to download


Subscription is free to qualifying UK subscribers

To read articles in full and features in the magazine, why not subscribe

Reprints available.

PharmaTimes Magazine print and digital versions have a total circulation of 23,184, including 8,000 NHS healthcare professionals: chief pharmacists, medicines management and primary care commissioners.

Follow us: @PharmaTimes on Twitter

Find a job

Website Search

Search News Search Magazine

Business Insight


Competitions News

Tickets still available for the PharmaTimes Sales Awards!  

Elert Signup!